版本:
中国

BRIEF-Ampliphi Biosciences provides update on phase 1 trial in chronic rhinosinusitis patients

Sept 20 Ampliphi Biosciences Corp:

* Ampliphi Biosciences provides update on phase 1 trial in chronic rhinosinusitis patients

* Through second of three cohorts, AB-SA01 was well tolerated

* Expect to report topline results and final results from trial later this year

* No drug-related serious adverse events were reported Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐